

UNITED THERAPEUTICS CORP

Form 8-K

November 29, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 24, 2004

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

000-26301

52-1984749

(State or Other
Jurisdiction of
Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification Number)

1110 Spring Street
Silver Spring, MD

20910

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01. Other Events.

On November 24, 2004, United Therapeutics Corporation issued a press release announcing United States Food and Drug Administration approval of intravenous dosing of Remodulin for the treatment of pulmonary arterial hypertension. A copy of this press release is attached hereto as Exhibit 99.1.

Item 9.01. Exhibits

(c) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press release dated November 24, 2004

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: November 29, 2004

By: /s/ Paul A. Mahon
Name: Paul A. Mahon
Title: General Counsel

EXHIBIT INDEX

Exhibit No.

Description of Exhibit

99.1

Press release dated November 24, 2004